| 2009 |
| |
|
Glenmark Generics Limited files DRHP and begins the process to list the generic subsidiary on the Indian stock exchanges. |
| |
|
Crofelemer progresses to final stage of Phase III trials in the US. |
| |
|
Formulations manufacturing facility commissioned in Nalagarh, Himachal Pradesh, India |
| |
|
GRC 10693 – Glenmark’s molecule for neuropathic pain, osteoarthritis, successfully completes Phase I trials. |
| |
|
Glenmark’s molecule for Osteoarthritis and Neuropathic Pain, GRC 15300, to enter Phase I trials. |
| |
|
Glenmark’s novel molecule for Diabetes, Melogliptin to enter Phase III trials. |
| |
|
Glenmark Generics ltd commissions its first exclusive R&D centre at Taloja, Maharashtra, India. |
|
| 2008 |
| |
|
Crofelemer receives fast-track designation status from the USFDA. With this, Glenmark expects to launch of Crofelmer by 2010. |
| |
|
SCRIP, the leading pharmaceutical magazine in the corld Crowns Glenmark as the "Best Pharma Company in the World – SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London |
| |
|
India’s first clinical R&D facility set up in Oxford, UK |
| |
|
Phase II–b trials for Oglemilast(GRC 3886) in Asthma initiated. |
| |
|
Glenmark completes preclinical development for initiating Phase I trials for GBR 500 – a monoclonal antibody for inflammation. |
| |
|
GRC 4039, Glenmark’s molecule for Rheumatoid Arthritis, enters Phase I trials |
| |
|
Receives USD 15 million as milestone payment from Forest for Oglemilast, GRC 3886 |
| |
|
Glenmark Pharma re-organizes its business. Glenmark Generics Limited (GGL) is incorporated as a subsidiary of Glenmark Pharmaceuticals Limited. |
| |
|
Receives USFDA approval for its state–of–the–art semi–solids manufacturing plant at Baddi. |
|
| 2007 |
| |
|
Acquires Medicamenta, a marketing and manufacturing company in the Czech Republic. |
| |
|
US Generic subsidiary concludes deal with Paul Capital to license and market generic drugs for the US market. |
| |
|
Glenmark’s molecule GRC 6211 for the potential treatment of pain, including osteoarthritis pain outlicensed to Eli Lily. Glenmark receives USD 45 million as upfront payment. |
| |
|
Glenmark wins Emerging Company Of The Year 2007 at The Economic Times Awards for Corporate Excellence. |
| |
|
Receives MHRA, UK approval for its semi-solid manufacturing plant at Baddi. |
|
| 2006 |
| |
|
Glenmark signs another outlicensing deal in discovery R&D with Merck KGaA, Germany for its diabetes molecule, Melogliptin. Glenmark receives USD 31 million as upfront payment. |
| |
|
Glenmark’s lead molecule Oglemilast (GRC 3886) enters Phase II clinical trials. |
| |
|
Received milestone payment from Forest Laboratories Inc for successful completion of Phase I trials. |
| |
|
R&D facility for NBE research commissioned in Switzerland. |
|
| 2005 |
| |
|
Launches commercial sales front–end in the US. |
| |
|
Concludes collaborative agreement on Oglemilast with Teijin Pharma for the Japan region. The potential deal value was USD 53 Mn. |
| |
|
Announces collaborative agreement with Napo pharmaceuticals Inc. for its anti–diarrheal compound Crofelemer. Glenmark gets Crofelemer rights in nearly 140 countries. |
| |
|
Acquires Servycal S.A. a marketing company in Argentina with strengths in oncology. |
| |
|
Acquires Bouwer Bartlett pty, ltd, a sales and marketing company in South Africa. |
| |
|
Commissions a new manufacturing facility at Baddi, Himachal Pradesh India. |
|
| 2004 |
| |
|
Glenmark strikes its first out-licensing deal for discovery R&D with Forest Laboratories for Oglemilast, its COPD/asthma molecule. The potential deal size is USD 190 mn and rights only for the North American region. |
| |
|
Acquires Laboratorios Klinger, Brazil together with its ANVISA approved manufacturing facility in order to expand its operations in the Latin American markets. |
| |
|
Commissions its own manufacturing facility at Goa to service exports to regulated markets viz. USA. |
| |
|
API manufacturing facility commissioned in Mohol, Maharashtra. |
|
| 2002 |
| |
|
Acquires an API manufacturing facility at Ankleshwar, Gujarat from GlaxoSmithKline Pharmaceuticals Ltd. |
|
| 2001 |
| |
|
Launches API manufacturing business by commissioning its first manufacturing facility for APIs in Kurkumbh, Maharashtra. |
|
| 2000 |
| |
|
Announces its IPO(Initial Public Offer). Issue oversubscribed 65 times. Market capitalization at USD 40 mn. |
| |
|
Enters the diabetes segment. |
| |
|
Acquires three brands from Lyka Labs. |
|